Results 141 to 150 of about 1,296 (182)
Some of the next articles are maybe not open access.
Perioperative experience with amrinone.
European journal of anaesthesiology. Supplement, 1992Amrinone is the only phosphodiesterase fraction III inhibitor currently available in the USA for the treatment of perioperative biventricular failure. Patients with chronic congestive heart failure (CHF) show down-regulation of the beta 1-adrenergic receptor with a decrease in receptor density and altered responses to catecholamines.
J H, Levy, J M, Bailey
openaire +1 more source
Toxicological Studies with Amrinone
1988Amrinone, 3-amino-5-(pyrid-4yl)-1,2-dihydropyridine-2one, an inhibitor of phosphodiesterases with positive inotropic and vasodilator activity, represents a prototype of a new class of drugs against cardiac failure (Alousi et al. 1979; Alousi and Farah 1980; Landmann and Loewe 1986). Its therapeutic value is limited because of multiple side-effects. The
H. Landmann, I. Frosch
openaire +1 more source
Amrinone-induced hepatotoxicity
American Journal of Health-System Pharmacy, 1984M E, Gilman, S C, Margolis
openaire +2 more sources
The effects of amrinone on contractility, Ca uptake and cAMP in smooth muscle
European Journal of Pharmacology, 1980Cornelis van Breemen, Roger F Palmer
exaly